| Patient | David Hume |
|---|---|
| Date of birth | 1962-05-07 |
| Identifiers | MRN HR-EN012-SYN; SSN (made up) 000-12-3049 |
| Document date | 2026-07-13 |
| Author | Fiona Gallacher, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Review four weeks after sigmoid colectomy. [S]
Mr. Hume returns four weeks after laparoscopic sigmoid colectomy with primary anastomosis. The liver MRI before surgery showed that the 9 mm lesion is a hemangioma, with no metastases. He went home on the third day. His stools are now formed, once or twice a day, with no blood, and his wounds have healed. He walks 20 minutes a day and is less tired since the two iron infusions. The pathology shows a pT3 N1a adenocarcinoma, with 1 of 22 lymph nodes involved, clear margins, and no lymphovascular or perineural invasion: stage IIIB. Dr. Mehta has advised three months of adjuvant CAPOX, starting next week, and sent a DPYD genotype test before the first capecitabine dose. He has been offered genetic counseling. [S]
| Element | Detail |
|---|---|
| Interval change | Colectomy four weeks ago; home on the third day |
| Bowel function | Formed stools once or twice a day; no bleeding |
| Pathology | pT3 N1a (1 of 22 nodes), R0, stage IIIB |
| Function | Walking 20 minutes a day; energy improving |
| Plan from oncology | CAPOX for three months from next week |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy improving; no fever |
| Gastrointestinal | Negative | Formed stools; no bleeding, pain, or urgency |
| Integumentary | Negative | Wounds healed |
| Neurological | Negative | No numbness or tingling of the hands or feet |
| Psychiatric | Negative | Mood good; PHQ-2 score 1; coping well |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Ferric carboxymaltose 750 mg intravenous infusion, two doses one week apart | 750 mg IV once a week for two doses | Intravenous route | 2026-06-01 to 2026-06-08 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-07-13 | Body height | 178 | cm | S |
| 2026-07-13 | Body weight | 82.5 | kg | S |
| 2026-07-13 | Body mass index (BMI) [Ratio] | 26 | kg/m2 | S |
| 2026-07-13 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-07-13 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-07-13 | Heart rate | 78 | /min | S |
| 2026-07-13 | Respiratory rate | 16 | /min | S |
| 2026-07-13 | Body temperature | 36.6 | Cel | S |
| 2026-07-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-07-13 | Carcinoembryonic Ag [Mass/volume] in Serum or Plasma | 2.2 | ng/mL | <=3 ng/mL | Normal | S |
| 2026-07-13 | Hemoglobin [Mass/volume] in Blood | 12.4 | g/dL | 13.2-16.6 g/dL | Low | S |
| 2026-07-13 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 82 | fL | 80-100 fL | Normal | S |
| 2026-07-13 | Leukocytes [#/volume] in Blood by Automated count | 6.8 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-07-13 | Neutrophils [#/volume] in Blood by Automated count | 4.1 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 2026-07-13 | Platelets [#/volume] in Blood by Automated count | 312 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-07-13 | Ferritin [Mass/volume] in Serum or Plasma | 186 | ng/mL | 30-400 ng/mL | Normal | S |
| 2026-07-13 | Iron saturation [Mass Fraction] in Serum or Plasma | 24 | % | 20-50% | Normal | S |
| 2026-07-13 | Creatinine [Mass/volume] in Serum or Plasma | 0.96 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-07-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 88 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-07-13 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 | U/L | 7-55 U/L | Normal | S |
| 2026-07-13 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-07-13 | Albumin [Mass/volume] in Serum or Plasma | 3.9 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-07-13 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S |
Vital signs recorded on 2026-07-13; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well, better color |
| Abdomen | Port-site scars healed; soft, non-tender; no hernia |
| Neurological | Baseline before oxaliplatin: light touch, vibration, and proprioception normal in hands and feet; ankle reflexes present |
| Skin | Palms and soles normal before capecitabine |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Adenocarcinoma of the sigmoid colon, suspected at presentation and confirmed by colonoscopic biopsy; synthetic modern diagnosis linked to the documented 1775 bowel disorder and its retrospective interpretation as colon cancer | active | confirmed | C18.7 | S — Synthetic diagnosis confirmed by biopsy and resection in the modern episode; the historical diagnosis remains a retrospective interpretation (R). |
| Iron deficiency anemia from chronic blood loss from the colon tumor | active | confirmed | D50.0 | S — Synthetic finding echoing the documented 'hemorrhage in the upper part of the intestines'; no blood count from his lifetime exists. |
| Hemangioma of the liver, 9 mm, segment VI; incidental finding characterized by MRI, not a metastasis | active | confirmed | D18.03 | S — Synthetic incidental finding; it addresses, and does not confirm, the unverified suggestion of liver spread. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | CEA after resection | Every 3 to 6 months for 2 years | Completed today | 2.2 ng/mL, normal, down from 6.4 before surgery |
| Laboratory | Blood count and iron studies 6 to 8 weeks after intravenous iron | Once after infusion | Completed today | Hemoglobin 12.4 g/dL, MCV 82 fL; ferritin 186 ng/mL, transferrin saturation 24 percent; neutrophils 4.1 and platelets 312 before chemotherapy |
| Laboratory | Kidney and liver function before chemotherapy | Before each cycle (oncology) | Completed today | Creatinine 0.96 mg/dL, eGFR 88; ALT 20 U/L, bilirubin 0.5 mg/dL, albumin 3.9 g/dL |
| Survey | Distress and depression screen (PHQ-2) | At each follow-up visit | Completed today | PHQ-2 score 1; coping well |
| Survey | Distress screen missed at the diagnosis visit | At each follow-up visit | Deferred | Missed at the visit three weeks after presentation, a deviation from the protocol. Today's screen is negative and he reports coping well, so no harm is evident; the screen is now on his visit checklist |
| Imaging | MRI of the liver | Once, for the indeterminate CT lesion | Up to date | Done before surgery: hemangioma; no metastases |
| Imaging | CT of the chest, abdomen, and pelvis | Every 6 to 12 months for 5 years | Due | First surveillance scan about six months after surgery |
| Examination | History and examination, wound and bowel function | Every 3 to 6 months for 2 years | Completed today | Wounds healed; formed stools; no ostomy |
| Examination | Peripheral neuropathy baseline | Before and at every visit during and after oxaliplatin | Completed today | Normal sensation and reflexes before the first dose |
| Medication safety | DPYD genotype before capecitabine | Once, before the first dose | Ordered | Sent by the oncology team; the result will be reviewed before cycle 1 |
| Referral | Genetic counseling for germline testing | At diagnosis of colorectal cancer, especially with a family history | Referred | Offered because his mother is reported to have died of a similar bowel illness; tumor mismatch-repair proficient |
| Self-management | Physical activity | Every visit | Completed today | Walking 20 minutes a day; goal of 150 minutes a week through chemotherapy |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Colon Cancer, Version 4.2025 (2025); Duration of Adjuvant Chemotherapy for Stage III Colon Cancer (IDEA collaboration). N Engl J Med 2018;378:1177-1188 (2018); AGA Clinical Practice Guidelines on the Gastrointestinal Evaluation of Iron Deficiency Anemia (2020); CMID: Clinical Monitoring Intelligence Database, colorectal cancer and anemia monographs (2026)
Follow-up: CAPOX cycle 1 next week with the oncology team. Primary care review after the fourth cycle, with blood count, CEA, and a neuropathy check. Next scheduled visit 2026-10-19: review two weeks after completing adjuvant CAPOX and start of survivorship surveillance. [S]